key: cord-0744632-ib1bbn1u authors: Wong, Carlos K. H.; Wong, Janet Y. H.; Tang, Eric H. M.; Au, C. H.; Wai, Abraham K. C. title: Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis date: 2020-11-13 journal: Sci Rep DOI: 10.1038/s41598-020-74988-9 sha: 2f8fcfd22b02be8876a70b3290b27f1b7f8bd310 doc_id: 744632 cord_uid: ib1bbn1u This systematic review and meta-analysis investigated the comorbidities, symptoms, clinical characteristics and treatment of COVID-19 patients. Epidemiological studies published in 2020 (from January–March) on the clinical presentation, laboratory findings and treatments of COVID-19 patients were identified from PubMed/MEDLINE and Embase databases. Studies published in English by 27th March, 2020 with original data were included. Primary outcomes included comorbidities of COVID-19 patients, their symptoms presented on hospital admission, laboratory results, radiological outcomes, and pharmacological and in-patient treatments. 76 studies were included in this meta-analysis, accounting for a total of 11,028 COVID-19 patients in multiple countries. A random-effects model was used to aggregate estimates across eligible studies and produce meta-analytic estimates. The most common comorbidities were hypertension (18.1%, 95% CI 15.4–20.8%). The most frequently identified symptoms were fever (72.4%, 95% CI 67.2–77.7%) and cough (55.5%, 95% CI 50.7–60.3%). For pharmacological treatment, 63.9% (95% CI 52.5–75.3%), 62.4% (95% CI 47.9–76.8%) and 29.7% (95% CI 21.8–37.6%) of patients were given antibiotics, antiviral, and corticosteroid, respectively. Notably, 62.6% (95% CI 39.9–85.4%) and 20.2% (95% CI 14.6–25.9%) of in-patients received oxygen therapy and non-invasive mechanical ventilation, respectively. This meta-analysis informed healthcare providers about the timely status of characteristics and treatments of COVID-19 patients across different countries. PROSPERO Registration Number: CRD42020176589 Data analysis. Three authors (CW, EHMT and CHA) extracted data using a standardized spreadsheet to record the article type, country of origin, surname of first author, year of publications, sample size, demographics, comorbidities, symptoms, laboratory and radiology results, pharmacological and non-pharmacological treatments. We aggregated estimates across 90 eligible studies to produce meta-analytic estimates using a random-effects model. For dichotomous outcomes, we estimated the proportion and its respective 95% confidence interval. For laboratory parameters as continuous outcomes, we estimated the mean and standard deviation from the median and interquartile range if the mean and standard deviation were not available from the study 14 , and calculated the mean and its respective 95% confidence intervals. Random-effect models on DerSimonian and Laird method were adopted due to the significant heterogeneity, checked by the I 2 statistics and the p values. I 2 statistic of < 25%, 25-75% and ≥ 75% is considered as low, moderate, high likelihood of heterogeneity. Pooled estimates were calculated and presented by using forest plots. Publication bias was estimated by Egger's regression test. Funnel plots of outcomes were also presented to assess publication bias. All statistical analyses were conducted using the STATA Version 13.0 (Statacorp, College Station, TX). The random effects model was generated by the Stata packages 'Metaprop' for proportions 15 and 'Metan' for continuous variables 16 . The selection and screen process are presented in Fig. 1 . A total of 241 studies were found by our searching strategy (71 in PubMed and 170 in Embase). 46 records were excluded due to duplication. After screening the abstracts and titles, 100 English studies were with original data and included in full-text screening. By further excluding 10 studies with not reporting symptoms presentation, laboratory findings, treatment and therapeutics, 90 studies 17-106 and 76 studies with more than one COVID-19 case 17 www.nature.com/scientificreports/ in China. Newcastle-Ottawa Quality Assessment Scale has been used to assess study quality of each included cohort study 107 . 30% (27/90) of included studies had satisfactory or good quality. The summary of the included study is shown in Table 1 . Of those 90 eligible studies, 11,028 COVID-19 patients were identified and included in the systematic review. More than half of patients (6336, 57.5%) were from mainland China. The pooled mean age was 45.8 (95% CI 38.6-52.5) years and 49.3% (pooled 95% CI 45.6-53.0%) of them were male. For specific comorbidity status, the most prevalent comorbidity was hypertension (18.1%, 95% CI 15.4-20.8%), followed by cardiovascular disease (11.8%, 95% CI 9.4-14.2%) and diabetes (10.4%, 95% CI 8.7-12.1%). The pooled prevalence (95% CI) of COPD, chronic kidney disease, liver disease and cancer were 2.0% (1.3-2.7%), 5.2% (1.7-8.8%), 2.5% (1.7-3.4%) and 2.1% (1.3-2.8%) respectively. Moderate to substantial heterogeneity between reviewed studies were found, with I 2 statistics ranging from 39.4 to 95.9% (p values between < 0.001-0.041), except for liver disease (I 2 statistics: 1.7%, p = 0.433). Detailed results for comorbidity status are displayed in Fig. 2 . Regarding the symptoms presented at hospital admission, the most frequent symptoms were fever (pooled prevalence: 72.4%, 95% CI 67.2-77.7%) and cough (pooled prevalence: 55.5%, 95% CI 50.7-60.3%). Sore throat (pooled prevalence: 16.2%, 95% CI 12.7-19.7%), dyspnoea (pooled prevalence: 18.8%, 95% CI 14.7-22.8%) and muscle pain (pooled prevalence: 22.1%, 95% CI 18.6-25.5%) were also common symptoms found in COVID-19 patients, but headache (pooled prevalence: 10.5%, 95% CI 8.7-12.4%), diarrhoea (pooled prevalence: 7.9%, 95% CI 6.3-9.6%), rhinorrhoea (pooled prevalence: 9.2%, 95% CI 5.6-12.8%) were less common. However, none of the included papers reported prevalence of anosmia and ageusia. The I 2 statistics varied from 68 p values < 0.001), indicating a high heterogeneity exists across studies. Figure 3 shows the pooled proportion of symptoms of patients presented at hospital. For laboratory parameters, white blood cell (pooled mean: 5.31 × 10 9 /L, 95% CI 5.03-5.58 × 10 9 /L), neutrophil (pooled mean: 3.60 × 10 9 /L, 95% CI 3.31-3.89 × 10 9 /L), lymphocyte (pooled mean: 1.11 × 10 9 /L, 95% CI www.nature.com/scientificreports/ Fig. 4 . Same with the comorbidity status and symptoms, high likelihood of heterogeneity was detected by I 2 statistics for a majority of clinical parameters. Figure 5 presents the distribution of the pharmacological treatments received for COVID-19 patients. 10 .6% of patients admitted to intensive care units (pooled 95% CI 8.1-13.2%). For drug treatment, 63.9% (pooled 95% CI 52.5-75.3%), 62.4% (pooled 95% CI 47.9-76.8%) and 29.7% (pooled 95% CI 21.8-37.6%) patients used antibiotics, antiviral, and corticosteroid, respectively. 41.3% (pooled 95% CI 14.3-68.3%) and 50.7% (pooled 95% CI 9.2-92.3%) reported using Lopinavir/Ritonavir and interferon-alpha as antiviral drug treatment, respectively. Among 14 studies reporting proportion of corticosteroid used, 7 studies (50%) specified the formulation of corticosteroid as systemic corticosteroid. The remaining one specified the use of methylprednisolone. No reviewed studies reported the proportion of patients receiving Ribavirin, Interferon-beta, or inotropes. The prevalence of radiological outcomes and non-pharmacological treatments were presented in Fig. 6 . Radiology findings detected chest X-ray abnormalities, with 74 This meta-analysis reveals the condition of global medical community responding to COVID-19 in the early phase. During the past 4 months, a new major epidemic focus of COVID-19, some without traceable origin, has been identified. Following its first identification in Wuhan, China, the virus has been rapidly spreading to Europe, North America, Asia, and the Middle East, in addition to African and Latin American countries. Three months since Wuhan CDC admitted that there was a cluster of unknown pneumonia cases related to Huanan Seafood Market and a new coronavirus was identified as the cause of the pneumonia 108 , as on 1 April, 2020, there have been 858,371 persons confirmed infected with COVID-19, affecting 202 countries and territories around the world. Although this rapid review is limited by the domination of reports from patients in China, and the patient population is of relative male dominance reflecting the gender imbalance of the Chinese population 109 , it provides essential information. In this review, the pooled mean age was 45.8 years. Similar to the MERS-CoV pandemic 110 , middle-aged adults were the at-risk group for COVID-19 infections in the initial phase, which was different from the H1N1 influenza pandemic where children and adolescents were more frequently affected 111 . Biological differences may affect the clinical presentations of infections; however, in this review, studies examining the asymptomatic COVID-19 infections or reporting any previous infections were not included. It is suggested that another systematic review should be conducted to compare the age-specific incidence rates between the pre-pandemic and post-pandemic periods, so as to understand the pattern and spread of the disease, and tailor specific strategies in infection control. Both sexes exhibited clinical presentations similar in symptomatology and frequency to those noted in other severe acute respiratory infections, namely influenza A H1N1 112 and SARS 113, 114 . These generally included fever, new onset or exacerbation of cough, breathing difficulty, sore throat and muscle pain. Among critically ill patients usually presented with dyspnoea and chest tightness 22, 29, 39, 72 , 141 (4.6%) of them with persistent or progressive hypoxia resulted in the requirement of intubation and mechanical ventilation 115 , while 194 (6.4%) of them required non-invasive ventilation, yielding a total of 11% of patients requiring ventilatory support, which was similar to SARS 116 . The major comorbidities identified in this review included hypertension, cardiovascular diseases and diabetes mellitus. Meanwhile, the percentages of patients with chronic renal diseases and cancer were relatively low. These chronic conditions influencing the severity of COVID-19 had also been noted to have similar effects in other respiratory illnesses such as SARS, MERS-CoV and influenza 117, 118 . Higher mortality had been observed among older patients and those with comorbidities. Early diagnosis of COVID-19 was based on recognition of epidemiological linkages; the presence of typical clinical, laboratory, and radiographic features; and the exclusion of other respiratory pathogens. The case definition had initially been narrow, but was gradually broadened to allow for the detection of more cases, as milder cases and those without epidemiological links to Wuhan or other known cases had been identified 119, 120 . Laboratory investigations among COVID-19 patients did not reveal specific characteristics-lymphopenia and elevated inflammatory markers such as CRP are some of the most common haematological and biochemical abnormalities, which had also been noticed in SARS 121 . None of these features were specific to COVID-19. Therefore, diagnosis should be confirmed by SARS-CoV-2 specific microbiological and serological studies, although initial management will continue to be based on a clinical and epidemiological assessment of the likelihood of a COVID-19 infection. Radiology imaging often plays an important role in evaluating patients with acute respiratory distress; however, in this review, radiological findings of SARS-CoV-2 pneumonia were non-specific. Despite chest radiograph www.nature.com/scientificreports/ www.nature.com/scientificreports/ usually revealed bilateral involvement and Computed Tomography usually showed bilateral multiple ground-glass opacities or consolidation, there were also patients with normal chest radiograph, implying that chest radiograph might not have high specificity to rule out pneumonia in COVID-19. Limited clinical data were available for asymptomatic COVID-19 infected persons. Nevertheless, asymptomatic infection could be unknowingly contagious 122 . From some of the official figures, 6.4% of 150 non-travelrelated COVID-19 infections in Singapore 123 , 39.9% of cases from the Diamond Princess cruise ship in Japan 124 , and up to 78% of cases in China as extracted on April 1st, 2020, were found to be asymptomatic 122 . 76% (68/90) studies based on hospital setting which provided care and disease management to symptomatic patients had limited number of asymptomatic cases of COVID-19 infection. This review calls for further studies about clinical data of asymptomatic cases. Asymptomatic infection intensifies the challenges of isolation measures. More global reports are crucially needed to give a better picture of the spectrum of presentations among all COVID-19 infected persons. Also, public health policies including social and physical distancing, monitoring and surveillance, as well as contact tracing, are necessary to reduce the spread of COVID-19. Concerning potential treatment regime, 62.4% of patients received antivirals or interferons (including oseltamivir, lopinavir-ritonavir, interferon alfa), while 63.9% received antibiotics (such as moxifloxacin, and ceftriaxone). In this review, around one-third of patients were given steroid, suggestive as an adjunct to IFN, or sepsis management. Interferon and antiviral agents such as ribavirin, and lopinavir-ritonavir were used during SARS, and the initial uncontrolled reports then noted resolution of fever and improvement in oxygenation and radiographic appearance 113, 125, 126 , without further evidence on its effectiveness. At the time of manuscript preparation, there has been no clear evidence guiding the use of antivirals 127 . Further research is needed to inform clinicians of the appropriate use of antivirals for specific groups of infected patients. Limitations of this meta-analysis should be considered. First, a high statistical heterogeneity was found, which could be related to the highly varied sample sizes (9 to 4226 patients) and study designs. Second, variations of follow-up period may miss the event leading to heterogeneity. In fact, some patients were still hospitalized in the included studies. Third, since only a few studies had compared the comorbidities of severe and non-severe patients, sensitivity analysis and subgroup analysis were not conducted. Fourthly, the frequency and severity of signs and symptoms reported in included studies, primarily based on hospitalized COVID-19 patients were over-estimated. Moreover, different cutoffs for abnormal laboratory findings were applied across countries, and counties within the same countries. Lastly, this meta-analysis reviewed only a limited number of reports written in English, with a predominant patient population from China. This review is expected to inform clinicians of the epidemiology of COVID-19 at this early stage. A recent report estimated the number of confirmed cases in www.nature.com/scientificreports/ www.nature.com/scientificreports/ China could reach as high as 232,000 (95% CI 161,000, 359,000) with the case definition adopted in 5th Edition. In this connection, further evidence on the epidemiology is in imminent need. www.nature.com/scientificreports/ Shrimp vendor identified as possible coronavirus 'patient zero, ' leaked document says Basic protective measures against the new coronavirus explo re?date=today %203-m&q=when%20 wil l%20cor onavi rus%20end ,%2Fm%2F01c pyy Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness Potential factors influencing repeated SARS outbreaks in China The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: a data-driven correlational report Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses Database of publications on coronavirus disease Impact of national containment measures on decelerating the increase in daily new cases of COVID-19 in 54 countries and 4 epicenters of the pandemic: comparative observational study Symptoms of Coronavirus Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range Metaprop: a Stata command to perform meta-analysis of binomial data metan: fixed-and random-effects meta-analysis Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of coronavirus disease 2019 in China A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan First case of coronavirus disease 2019 (COVID-19) pneumonia in Taiwan First case of 2019 novel coronavirus in the United States Novel coronavirus infection in hospitalized infants under 1 year of age in China First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study A novel coronavirus from patients with pneumonia in China First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand COVID-19 in 2 persons with mild upper respiratory tract symptoms on a cruise ship Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission The first Vietnamese case of COVID-19 acquired from China First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region Transmission of 2019-nCoV infection from an asymptomatic contact in Germany Potential presymptomatic transmission of SARS-CoV-2 Presumed asymptomatic carrier transmission of COVID-19 A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period Transmission of COVID-19 in the terminal stages of the incubation period: a familial cluster Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child A well infant with coronavirus disease 2019 with high viral load CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan. China Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai CT imaging features of 2019 novel coronavirus (2019-nCoV) Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) A case report of neonatal 2019 coronavirus disease in China The first 2019 novel coronavirus case in Nepal Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19 Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu Province: a multicenter descriptive study Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multicenter study in Wenzhou city Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression Initial clinical features of suspected coronavirus disease in two emergency departments outside of Hubei Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen Clinical features and treatment of COVID-19 patients in northeast Chongqing Characteristics of COVID-19 infection in Beijing Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study Emerging 2019 novel coronavirus (2019-nCoV) pneumonia Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19 Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Clinical features of COVID-19 in elderly patients: A comparison with young and middleaged patients Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Eleven faces of coronavirus disease 2019 Perinatal transmission of COVID-19 associated SARS-CoV-2: should we worry? Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak Clinical progression of patients with COVID-19 in Shanghai The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan Covid-19 National Emergency Response Center E & Case Management Team KCfDC, Prevention. Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea Insight into COVID-2019 for pediatricians Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses New virus discovered by Chinese scientists investigating pneumonia outbreak 2019 年国民经济运行总体平稳 发展主要预期目标较好实现 (In 2019, the overall stable development of the national economic operation is expected to achieve the main goals MERS transmission and risk factors: a systematic review Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis Epidemiological and clinical characteristics of the outbreak of 2009 pandemic influenza A (H1N1) at a middle school in Luoyang A major outbreak of severe acute respiratory syndrome in Hong Kong Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Critically ill patients with severe acute respiratory syndrome Severe acute respiratory syndrome Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study 新型冠状病毒肺炎诊疗方案 (试行第七版) (Clinical Guideline for Novel Coronavirus Pneumonia-Interim 7th Edition Severe acute respiratory syndrome: pertinent clinical characteristics and therapy Covid-19: four fifths of cases are asymptomatic, China figures indicate Presymptomatic transmission of SARS-CoV-2-Singapore Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship Identification of severe acute respiratory syndrome in Canada A cluster of cases of severe acute respiratory syndrome in Hong Kong A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19 None. C.W., J.W. and A.W. contributed equally to all aspects of study design, conduct, data interpretation, and the writing of the manuscript. C.W., E.T. and C.H.A. contributed to eligibility screening, data extraction from eligible studies, and data analysis and interpretation. There was no funding source for this study. The authors declare no competing interests. Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-74988 -9.Correspondence and requests for materials should be addressed to A.K.W.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.